Millendo Raises $62m, Licenses AstraZeneca Drug
This article was originally published in Scrip
Executive Summary
Millendo Therapeutics raised $62m in a Series B round led by New Enterprise Associates and the endocrine disorder-focused biotech firm licensed a polycystic ovary syndrome (PCOS) drug candidate from AstraZeneca PLC in a deal that will widen the company's focus.